Solid Biosciences (SLDB) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Solid Biosciences

NasdaqGS•Healthcare•Biotechnology

$9.93-0.32(-0.03%)Pre-market

Market Cap

$1.26B

P/B

3.4x

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

How this company scores

WeakMetricSide Score: 31/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (4/25).

Profitability4/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/B · 3.4x5y range 0.2x – 3.4x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.26B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-210.52M
TTM Op. Income: $-212.15M
Q. Op. Income: $-57.38M
TTM Net Income: $-207.10M
Q. Net Income: $-54.80M
EPS: $-0.38
Shares Out.: $143.69M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-210.52M and TTM operating income of $-212.15M show growth is flowing through to the bottom line. However, net income is negative at $207.10M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -5738400000.0%
Net Margin: -5479900000.0%

Op. margin of -5738400000.0% is down 1569100000.0% YoY — costs are rising relative to revenue. Net margin at -5479900000.0% Across the last 8 quarters, operating margin has fallen for 7 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 3.4x

P/S of 0.0x and P/B of 3.4x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $420.58M
Cash: $159.39M
Long-Term Debt: N/A
Book Value: $374.07M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-52.59M
TTM Free Cash Flow: $-187.81M
FCF Margin: N/A
FCF / Net Income: 0.9

TTM FCF of $-187.81M on $-52.59M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 7 consecutive quarters — a weakening trend.